Although biotechnology is still somewhat of a young industry, and for the most part, not yet profitable, it has the technological resources and capabilities now to tackle the challenges of neglected diseases, said Christopher Earl, CEO of BIO Ventures for Global Health. (BioWorld Financial Watch) Read More
